•  
  •  
  •  
  •  

2026-05-15 17:58:26

  • Home
  • Commodities
  • Industry News
  • IPO
  • Mutual Funds
  • Others
  • Research
  • Watch List
Latest News
  • Deep Industries Ltd consolidated Q4 FY2025-26 loss at Rs. 14.35 crores
  • Data Patterns India Ltd Q4FY26 PAT climbs to Rs. 138.38 crores
  • KRBL Ltd posts consolidated PAT of Rs. 155.38 crores in Q4 FY26
  • Pitti Engineering Ltd consolidated Q4 FY2026 profit declines to Rs. 26.61 crores
  • Mukand Ltd reports consolidated PAT of Rs. 554.98 crores in Q4 FY2026

Keywords Selected:  Lupin

Research

  • Lupin - Q1FY23 Result Update - Margin disappointment continues - HOLD

Stock Report

  • Lupin Receives U.S. FDA Approval for Famotidine Injection, USP
  • Lupin Ltd recommends dividend of Rs. 18
  • Lupin Ltd posts Q4FY26 consolidated PAT climbs to Rs. 1460.34 crores
  • Lupin Receives U.S. FDA Approval for Glycerol Phenylbutyrate Oral Liquid
  • Lupin Launches Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets in the United States
  • USFDA inspection at Somerset facility of Lupin Ltd
  • Lupin Pharmaceuticals, Inc, USA enters into settlement agreement with Humana Inc
  • Lupin Launches Dapagliflozin Tablets in the United States
  • Lupin announces approval of Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets in the United States
  • Lupin Announces the Approval of Dapagliflozin Tablets in the United States
  • Lupin Completes Acquisition of VISUfarma
  • Lupin Receives Tentative Approval from U.S. FDA for Sugammadex Injection
  • Lupin Receives Tentative Approval from U.S. FDA for Pitolisant Tablets
  • Lupin and Zydus Sign Licensing Agreement for Co-marketing Innovative Semaglutide Injection in India
  • Lupin Ltd gets two observations from USFDA for Ankleshwar facility
  • Lupin Receives EIR from US FDA for its Goa Facility
  • Vinita Gupta, Lupin CEO, Named to the 2026 CNBC Changemakers List of Women Transforming Business for Making Medicines Accessible and Affordable for Americans
  • Lupin announces the approval and launch of Brivaracetam Oral Solution in the United States
  • Lupin receives European Commission approval for Biosimilar Ranibizumab
  • Lupin signs License and Supply Agreement with Spektus to Commercialize Novel Antidepressant DeslaFlex™ in Canada
  • Lupin and Galenicum Sign License and Supply Agreement for Semaglutide in 23 Countries
  • Lupin signs exclusive licensing agreement with Gan & Lee Pharmaceuticals for novel GLP-1 receptor agonist
  • Lupin signs exclusive licensing agreement with Neopharmed for Gastroenterology Brand PlasilĀ® in the Philippines and Brazil
  • Lupin receives Positive CHMP Opinion for Biosimilar Ranibizumab

Latest Post

  • Deep Industries Ltd consolidated Q4 FY2025-26 loss at Rs. 14.35 crores
  • Data Patterns India Ltd Q4FY26 PAT climbs to Rs. 138.38 crores
  • KRBL Ltd posts consolidated PAT of Rs. 155.38 crores in Q4 FY26
  • Pitti Engineering Ltd consolidated Q4 FY2026 profit declines to Rs. 26.61 crores
  • Mukand Ltd reports consolidated PAT of Rs. 554.98 crores in Q4 FY2026


Announcement

To Advertise in our website please e-mail us at advertisement@equitybulls.com
Companies can send their Press Releases to pressrelease@equitybulls.com

Links

  • Home
  • Contact
  • Our Team

Contact

The website is developed and maintained by Chennai Scripts
C-4, Podhigai Flats, Pillayar Koil Street, Nesapakkam
Chennai
Tamil Nadu
India
600078
E-mail: chennaiscripts@gmail.com
Mobile Phone Number: +91-88776-69935
www.chennaiscripts.com

Website Created & Maintained by : Chennai Scripts
Nesapakkam, Chennai - 600 078,
Tamil Nadu, India

Disclaimer Copyright © - 2025